<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">5. Fibrin Handling for Bioactive Compounds Delivery</segment>
<segment id="2" parent="1002" relname="preparation">5.1. Tuning Fibrin Intrinsic Characteristics</segment>
<segment id="3" parent="1004" relname="span">Bioactive compounds</segment>
<segment id="4" parent="3" relname="elaboration">including growth factors , cytokines , drugs , and nucleic acids can be easily entrapped in the fibrin matrix</segment>
<segment id="5" parent="1004" relname="means">by mixing them with fibrinogen or thrombin .</segment>
<segment id="6" parent="1002" relname="joint">In general , fibrin matrix remains porous regardless the conditions and/or thrombin and fibrinogen ratios .</segment>
<segment id="7" parent="1002" relname="joint">However , increasing fibrinogen and/or thrombin concentrations densifies the structure of a fibrin gel</segment>
<segment id="8" parent="1008" relname="span">and reduces its degradation rate ,</segment>
<segment id="9" parent="1009" relname="span">thus slowing down the diffusion of loaded molecules</segment>
<segment id="10" parent="9" relname="elaboration">( e.g. , FGF ) .</segment>
<segment id="11" parent="1011" relname="span">In addition , the release profile of active compounds is affected by their physicochemical properties</segment>
<segment id="12" parent="11" relname="elaboration">including partition coefficient , size and functional groups .</segment>
<segment id="13" parent="1016" relname="span">For example , hydrophilic molecules readily leach out</segment>
<segment id="14" parent="13" relname="elaboration">( e.g. , erythromycin , mitomycin C , fluorouracil etc. ) ,</segment>
<segment id="15" parent="1017" relname="span">while hydrophobic molecules , or those</segment>
<segment id="16" parent="15" relname="elaboration">which display a strong chemical affinity for the matrix components ,</segment>
<segment id="17" parent="1018" relname="span">are released more gradually</segment>
<segment id="18" parent="17" relname="elaboration">( e.g. , streptomycin , sulfamethoxazole-trimethoprim , cefazolin , enocitabine etc. ) .</segment>
<segment id="19" parent="1020" relname="span">Thus , some compounds need to be modified chemically</segment>
<segment id="20" parent="1021" relname="span">to become more hydrophobic ,</segment>
<segment id="21" parent="20" relname="elaboration">resulting in a prolonged retention within the matrix .</segment>
<segment id="22" parent="1023" relname="span">Conversely , a proteolytic degradation may be required</segment>
<segment id="23" parent="22" relname="purpose">to speed up the diffusion process .</segment>
<segment id="24" parent="1025" relname="span">Lastly , fibrin matrix proteolysis through the action of thrombin or plasmin induces the release of entrapped compounds .</segment>
<segment id="25" parent="1027" relname="span">In order to restrict this breakdown of the matrix ,</segment>
<segment id="26" parent="1028" relname="span">the co-entrapment of proteolysis inhibitors</segment>
<segment id="27" parent="26" relname="elaboration">( aprotinin , matrix metalloproteinases inhibitors such as galardin )</segment>
<segment id="28" parent="1026" relname="same_unit">was investigated .</segment>
<segment id="29" parent="1031" relname="span">Ahmed et al. identified in their model</segment>
<segment id="30" parent="29" relname="elaboration">( i.e. , chondroprogenitor clonal cell line )</segment>
<segment id="31" parent="1032" relname="span">the enzymes</segment>
<segment id="32" parent="31" relname="elaboration">responsible for fibrin gel breakdown .</segment>
<segment id="33" parent="1036" relname="attribution">It appeared</segment>
<segment id="34" parent="1036" relname="span">that metalloproteinases</segment>
<segment id="35" parent="34" relname="elaboration">( MMP-2 , MMP-3 , MMP-9 )</segment>
<segment id="36" parent="1034" relname="same_unit">were secreted concomitantly with fibrin hydrogels breakdown .</segment>
<segment id="37" parent="1037" relname="sequence">They also noted high plasmin activity in the conditioned media during hydrogel breakdown .</segment>
<segment id="38" parent="39" relname="attribution">Then , they demonstrated</segment>
<segment id="39" parent="1038" relname="span">that aprotinin and galardin , in combination or separately , prevented fibrin hydrogels degradation .</segment>
<segment id="40" parent="1041" relname="preparation">Figure 4</segment>
<segment id="41" parent="1041" relname="span">summarizes the modifications</segment>
<segment id="42" parent="1042" relname="span">which can be made on fibrin matrix</segment>
<segment id="43" parent="42" relname="purpose">to regulate the release of entrapped agents .</segment>
<segment id="44" parent="1044" relname="span">5.2. Modifying Fibrin and/or Active Agents for Efficient Combination and Delivery</segment>
<segment id="45" parent="1045" relname="contrast">In some instances , fibrin exhibits innate affinity for therapeutics and growth factors</segment>
<segment id="46" parent="1045" relname="contrast">but in other cases , the covalent attachment of these compounds to fibrin is considered .</segment>
<segment id="47" parent="1048" relname="span">This generally requires chemical modifications with reactive functional groups</segment>
<segment id="48" parent="47" relname="elaboration">( thiols , azides )</segment>
<segment id="49" parent="1048" relname="result">allowing a stable association .</segment>
<segment id="50" parent="1002" relname="joint">Then , reduction/hydrolysis reactions or enzymatic cleavage mediate the release of active molecules .</segment>
<segment id="51" parent="52" relname="attribution">It was shown</segment>
<segment id="52" parent="1051" relname="span">that this approach prolongs the delivery phase of growth factors for example .</segment>
<segment id="53" parent="1053" relname="span">As another illustration , covalently binding of BMP and RGD sequences to fibrin allows interactions with bone marrow stromal cells through integrin surface receptors</segment>
<segment id="54" parent="53" relname="elaboration">that triggered downstream signaling pathways .</segment>
<segment id="55" parent="1002" relname="joint">More sophisticated constructions have been tested .</segment>
<segment id="56" parent="1056" relname="span">Starting from BMP-2 , Schmoekel et al. propose a tripartite fusion protein</segment>
<segment id="57" parent="56" relname="elaboration">denoted as TG-pl-BMP-2 .</segment>
<segment id="58" parent="1059" relname="span">Under the control of the blood transglutaminase factor XIIIa , the N-terminal transglutaminase substrate domain</segment>
<segment id="59" parent="58" relname="restatement">( TG )</segment>
<segment id="60" parent="1058" relname="same_unit">provides a covalent attachment to fibrin during coagulation .</segment>
<segment id="61" parent="1062" relname="span">In addition , upon the action of cell-activated plasmin , the central plasmin substrate domain</segment>
<segment id="62" parent="61" relname="restatement">( pl )</segment>
<segment id="63" parent="1061" relname="same_unit">gives a cleavage site for the local release of the attached growth factor from the fibrin matrix .</segment>
<segment id="64" parent="1002" relname="joint">Lastly , the C-terminal human BMP-2 domain displays an osteogenic activity .</segment>
<segment id="65" parent="1002" relname="joint">As an alternative to active molecules derivatization , fibrin functionalization can also be achieved .</segment>
<segment id="66" parent="1068" relname="span">For example ,</segment>
<segment id="67" parent="66" relname="purpose">to facilitate BMP interaction with a fibrin matrix ,</segment>
<segment id="68" parent="1067" relname="same_unit">Yang et al. grafted heparin onto fibrin ,</segment>
<segment id="69" parent="1066" relname="same_unit">this leading to electrostatic interactions between the negative charges of heparin sulfate groups , and the positive charges of BMPs amino acid residues .</segment>
<segment id="70" parent="1070" relname="span">Interestingly , heparin presence slowed down fibrin degradation , and consequently the release of loaded BMPs .</segment>
<segment id="71" parent="70" relname="elaboration">Similar observations were made with FGF .</segment>
<segment id="72" parent="1073" relname="span">Despite positive effects</segment>
<segment id="73" parent="72" relname="elaboration">reported in literature ,</segment>
<segment id="74" parent="1072" relname="span">there are several drawbacks to fibrin or growth factors/proteins functionalization .</segment>
<segment id="75" parent="1002" relname="joint">First of all , it requires specific skills ,</segment>
<segment id="76" parent="1002" relname="joint">and it is time consuming and expensive .</segment>
<segment id="77" parent="1002" relname="joint">Furthermore , proteins functionality can be altered by these modifications .</segment>
<segment id="78" parent="1078" relname="span">Indeed , covalent binding can mask active sites ,</segment>
<segment id="79" parent="78" relname="result">thus affecting their bioactivity .</segment>
<segment id="80" parent="1080" relname="span">As an alternative , non-modified compounds can be internalized into particles ,</segment>
<segment id="81" parent="80" relname="purpose">to slow down their release .</segment>
<segment id="82" parent="1082" relname="span">Wang et al. developed a sophisticated system</segment>
<segment id="83" parent="82" relname="elaboration">which could serve to deliver low-molecular weight hydrophilic drugs .</segment>
<segment id="84" parent="1084" relname="span">They used an antithrombosis drug</segment>
<segment id="85" parent="84" relname="elaboration">( i.e. , TirofibanÂ® ) as a drug model .</segment>
<segment id="86" parent="1085" relname="sequence">Drug-loaded liposomes were first encapsulated in a fibrin gel ,</segment>
<segment id="87" parent="1087" relname="span">and then combined to chitosan .</segment>
<segment id="88" parent="1088" relname="span">To document/characterize the in vitro drug release profile ,</segment>
<segment id="89" parent="1089" relname="span">different parameters were studied</segment>
<segment id="90" parent="89" relname="elaboration">including the surface charge of liposomes , the pore size of chitosan structure , and the crosslinking degree of fibrin gels .</segment>
<segment id="91" parent="1092" relname="span">All these experimental conditions offered different prolonged releases</segment>
<segment id="92" parent="91" relname="elaboration">without altering the composite bioactivity .</segment>
<segment id="93" parent="1092" relname="elaboration">All these modifications are summarized in</segment>
<segment id="94" parent="95" relname="preparation">Figure 4</segment>
<segment id="95" parent="1093" relname="span">.</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="joint"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1008" type="span" parent="1002" relname="joint"/>
<group id="1009" type="span" parent="8" relname="result"/>
<group id="1011" type="span" parent="1002" relname="joint"/>
<group id="1014" type="multinuc" parent="1002" relname="joint"/>
<group id="1015" type="multinuc" parent="1014" relname="same_unit"/>
<group id="1016" type="span" parent="1015" relname="same_unit"/>
<group id="1017" type="span" parent="1015" relname="same_unit"/>
<group id="1018" type="span" parent="1014" relname="same_unit"/>
<group id="1020" type="span" parent="1002" relname="joint"/>
<group id="1021" type="span" parent="19" relname="purpose"/>
<group id="1022" type="multinuc" parent="1002" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="sequence"/>
<group id="1025" type="span" parent="1022" relname="sequence"/>
<group id="1026" type="multinuc" parent="24" relname="purpose"/>
<group id="1027" type="span" parent="1026" relname="same_unit"/>
<group id="1028" type="span" parent="25" relname="elaboration"/>
<group id="1029" type="multinuc" parent="1022" relname="sequence"/>
<group id="1030" type="multinuc" parent="1029" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="same_unit"/>
<group id="1032" type="span" parent="1030" relname="same_unit"/>
<group id="1034" type="multinuc" parent="1029" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="span" parent="1035" relname="span"/>
<group id="1037" type="multinuc" parent="1029" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="sequence"/>
<group id="1040" type="span" parent="1002" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="span" parent="41" relname="elaboration"/>
<group id="1044" type="span" parent="1002" relname="joint"/>
<group id="1045" type="multinuc" parent="44" relname="elaboration"/>
<group id="1047" type="span" parent="1002" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="span"/>
<group id="1051" type="span" parent="1002" relname="joint"/>
<group id="1053" type="span" parent="1002" relname="joint"/>
<group id="1056" type="span" parent="1002" relname="joint"/>
<group id="1058" type="multinuc" parent="1002" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="same_unit"/>
<group id="1061" type="multinuc" parent="1002" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="same_unit"/>
<group id="1066" type="multinuc" parent="1002" relname="joint"/>
<group id="1067" type="multinuc" parent="1066" relname="same_unit"/>
<group id="1068" type="span" parent="1067" relname="same_unit"/>
<group id="1070" type="span" parent="1002" relname="joint"/>
<group id="1072" type="span" parent="1002" relname="joint"/>
<group id="1073" type="span" parent="74" relname="concession"/>
<group id="1078" type="span" parent="1002" relname="joint"/>
<group id="1080" type="span" parent="1002" relname="joint"/>
<group id="1082" type="span" parent="1002" relname="joint"/>
<group id="1084" type="span" parent="1002" relname="joint"/>
<group id="1085" type="multinuc" parent="1002" relname="joint"/>
<group id="1086" type="multinuc" parent="1085" relname="sequence"/>
<group id="1087" type="span" parent="1086" relname="joint"/>
<group id="1088" type="span" parent="87" relname="purpose"/>
<group id="1089" type="span" parent="88" relname="elaboration"/>
<group id="1090" type="span" parent="1086" relname="joint"/>
<group id="1091" type="span" parent="1090" relname="span"/>
<group id="1092" type="span" parent="1091" relname="span"/>
<group id="1093" type="span" parent="1091" relname="elaboration"/>
	</body>
</rst>
